Real-world Data for the Renal Safety of Abemaciclib Combined with Bisphosphonate in HR+/HER2- Advanced Breast Cancer

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2022 Nov 9

PMID 36351632

Authors

Chunfang Hao

Xuedong Bai

Jie Zhang

Wenjing Meng

Zhongsheng Tong

Affiliations

Soon will be listed here.

Abstract

Objective: Our study evaluated the renal safety of abemaciclib plus endocrine therapy (ET) with bisphosphonate as a treatment option for hormone receptor positive, human epidermal growth factor receptor 2 (HER-2) negative (HR+/HER2-) advanced breast cancer (ABC), especially with bone metastasis.

Methods: Data were collected from HR+/HER2- ABC patients who received abemaciclib with ET between March 2021 and May 2022 in a single medical center in China. We performed an analysis of the change in serum creatine (Cr) and creatine clearance (CrCl), time to first abnormal Cr value, and Common Terminology Criteria for Adverse Events grade of increased creatinine.

Results: A total of 210 patients were included in the final analysis, with a median age of 56 years and a median weight of 65 kg. Any grade laboratory-assessing increased Cr occurred in 87.1% of patients, while CrCl rarely went down to 30 ml/min. Associations between start dose with grade of increased Cr and menopausal status with alert value, which is defined as creatinine clearance <30 ml/min, were indicated.

Conclusion: This study shows that abemaciclib combined with bisphosphonate would be safe for renal function in HR+/HER2- ABC patients with bone metastases.

Citing Articles

Efficacy and Safety of Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies.

Su H, Lin H, Tam K Target Oncol. 2024; 20(1):71-88.

PMID: 39656361 DOI: 10.1007/s11523-024-01118-0.

Challenges of Renal Function Assessment in Breast Cancer Patients Treated With Abemaciclib: A Case Report.

Ferreira A, Brito da Silva J, Chuva M, Costa J, Pereira D Cureus. 2024; 16(8):e67714.

PMID: 39318897 PMC: 11420996. DOI: 10.7759/cureus.67714.

Real-world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/HER2- advanced breast cancer.

Hao C, Bai X, Zhang J, Meng W, Tong Z Thorac Cancer. 2022; 14(1):68-72.

PMID: 36351632 PMC: 9807446. DOI: 10.1111/1759-7714.14715.

References

Markowitz G, Appel G, Fine P, Fenves A, Loon N, Jagannath S . Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001; 12(6):1164-1172. DOI: 10.1681/ASN.V1261164. View

Banerjee D, Asif A, Striker L, Preston R, Bourgoignie J, Roth D . Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis. 2003; 41(5):E18. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Smetana S, Michlin A, Rosenman E, Biro A, Boaz M, Katzir Z . Pamidronate-induced nephrotoxic tubular necrosis--a case report. Clin Nephrol. 2004; 61(1):63-7. DOI: 10.5414/cnp61063. View

Chappell J, Turner P, Pak Y, Bacon J, Chiang A, Royalty J . Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2018; 105(5):1187-1195. PMC: 6465099. DOI: 10.1002/cpt.1296. View

Barri Y, Munshi N, Sukumalchantra S, Abulezz S, Bonsib S, Wallach J . Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int. 2004; 65(2):634-41. DOI: 10.1111/j.1523-1755.2004.00426.x. View

Slamon D, Neven P, Chia S, Fasching P, De Laurentiis M, Im S . Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2019; 382(6):514-524. DOI: 10.1056/NEJMoa1911149. View

Finn R, Martin M, Rugo H, Jones S, Im S, Gelmon K . Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016; 375(20):1925-1936. DOI: 10.1056/NEJMoa1607303. View

Bai X, Zhang X, Xiang W, Wang Y, Cao Y, Geng G . Time tracking and multidimensional influencing factors analysis on female breast cancer mortality: Evidence from urban and rural China between 1994 to 2019. Front Public Health. 2022; 10:1000892. PMC: 9549912. DOI: 10.3389/fpubh.2022.1000892. View

10.

Slamon D, Neven P, Chia S, Fasching P, De Laurentiis M, Im S . Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018; 36(24):2465-2472. DOI: 10.1200/JCO.2018.78.9909. View

11.

Sledge Jr G, Toi M, Neven P, Sohn J, Inoue K, Pivot X . MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017; 35(25):2875-2884. DOI: 10.1200/JCO.2017.73.7585. View

12.

Zhang Q, Sun T, Yin Y, Li H, Yan M, Tong Z . MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study. Ther Adv Med Oncol. 2020; 12:1758835920963925. PMC: 7586037. DOI: 10.1177/1758835920963925. View

13.

Xu B, Zhang Q, Zhang P, Hu X, Li W, Tong Z . Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med. 2021; 27(11):1904-1909. DOI: 10.1038/s41591-021-01562-9. View

14.

Miller P, Jamal S, Evenepoel P, Eastell R, Boonen S . Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Miner Res. 2013; 28(10):2049-59. DOI: 10.1002/jbmr.2058. View

15.

Rugo H, Huober J, Garcia-Saenz J, Masuda N, Sohn J, Andre V . Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. Oncologist. 2020; 26(1):e53-e65. PMC: 7794176. DOI: 10.1002/onco.13531. View

16.

Sledge Jr G, Toi M, Neven P, Sohn J, Inoue K, Pivot X . The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2019; 6(1):116-124. PMC: 6777264. DOI: 10.1001/jamaoncol.2019.4782. View

17.

Goetz M, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J . MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017; 35(32):3638-3646. DOI: 10.1200/JCO.2017.75.6155. View

18.

Turner N, Slamon D, Ro J, Bondarenko I, Im S, Masuda N . Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018; 379(20):1926-1936. DOI: 10.1056/NEJMoa1810527. View

19.

Tripathy D, Im S, Colleoni M, Franke F, Bardia A, Harbeck N . Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018; 19(7):904-915. DOI: 10.1016/S1470-2045(18)30292-4. View

20.

Slamon D, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S . Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021; 32(8):1015-1024. DOI: 10.1016/j.annonc.2021.05.353. View